Literature DB >> 33299382

A prospective comparative dosimetric study between diffusion weighted MRI (DWI) & T2-weighted MRI (T2W) for target delineation and planning in cervical cancer brachytherapy.

Rishabh Kumar1,2, Geeta S Narayanan3, Bhaskar Vishwanthan3, Sowmya Narayanan4, Sanjeet Mandal3.   

Abstract

AIM: To evaluate the difference between GTVBT (Gross Tumor Volume at Brachytherapy) and HR CTV (High Risk Clinical Tumor Volume) delineated with DWI and T2W MRI. To evaluate doses to organs at risk and targets from plans generated using T2W and DWI.
BACKGROUND: Functional imaging with DWI can improve cervical tumor distinction as it is more sensitive than T2W MRI even in detecting parametrial invasion. This study does a dosimetric comparison between a T2W and DWI based plan.
METHODS: Fifty carcinoma cervix patients were subjected to MRI based brachytherapy. T2W and a diffusion weighted sequence were acquired. Target delineation and brachytherapy planning was done on both T2W and DWI. Standard DVH parameters were recorded and the treatment was given using the plan generated from T2W images.
RESULTS: GTVBT and HRCTV contours on DWI were different when compared with T2W. Mean GTVBT volume on T2W and DWI was 5.25 and 5.23, respectively (p value 0.8). Mean HRCTV on T2W and DWI was 28.3 and 27 cc, respectively (p value 0.003). Planning on the above volumes resulted in a superior coverage in terms of HRCTV D90 and D100 for DWI based plan, HRCTV D90 - 735.1 and 741 cGy for T2W and DWI, respectively (p value 0.006), HRCTV D100 - 441.05 and 444.5 for T2W and DWI plans, respectively (p value = 0.006). Doses to the OAR were not significantly increased.
CONCLUSION: GEC ESTRO based contouring guidelines cover all the functionally abnormal areas on DWI. DWI should only be used as a supplement to T2W for contouring target volumes.
© 2020 Published by Elsevier B.V. on behalf of Greater Poland Cancer Centre.

Entities:  

Keywords:  ADC; Brachytherapy; Cervical cancer; Diffusion weighted imaging; IGABT; MRI

Year:  2020        PMID: 33299382      PMCID: PMC7691538          DOI: 10.1016/j.rpor.2020.08.008

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  25 in total

1.  Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.

Authors:  Richard Pötter; Christine Haie-Meder; Erik Van Limbergen; Isabelle Barillot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Beth Erickson; Stefan Lang; An Nulens; Peter Petrow; Jason Rownd; Christian Kirisits
Journal:  Radiother Oncol       Date:  2006-01-05       Impact factor: 6.280

2.  The utility of diffusion-weighted MR imaging in cervical cancer.

Authors:  Jianyu Chen; Yun Zhang; Biling Liang; Zehong Yang
Journal:  Eur J Radiol       Date:  2009-05-13       Impact factor: 3.528

Review 3.  Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.

Authors:  Christine Haie-Meder; Richard Pötter; Erik Van Limbergen; Edith Briot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Taran Paulsen Hellebust; Christian Kirisits; Stefan Lang; Sabine Muschitz; Juliana Nevinson; An Nulens; Peter Petrow; Natascha Wachter-Gerstner
Journal:  Radiother Oncol       Date:  2005-03       Impact factor: 6.280

4.  Apparent diffusion coefficients in GEC ESTRO target volumes for image guided adaptive brachytherapy of locally advanced cervical cancer.

Authors:  Søren Haack; Erik Morre Pedersen; Sune N Jespersen; Jesper F Kallehauge; Jacob Christian Lindegaard; Kari Tanderup
Journal:  Acta Oncol       Date:  2010-10       Impact factor: 4.089

5.  Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy.

Authors:  Alexandra Taylor; Andrea G Rockall; Rodney H Reznek; Melanie E B Powell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-29       Impact factor: 7.038

6.  Correction of diffusion-weighted magnetic resonance imaging for brachytherapy of locally advanced cervical cancer.

Authors:  Søren Haack; Jesper F Kallehauge; Sune N Jespersen; Jacob C Lindegaard; Kari Tanderup; Erik M Pedersen
Journal:  Acta Oncol       Date:  2014-07-14       Impact factor: 4.089

7.  Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer.

Authors:  Vanessa N Harry; Scott I Semple; Fiona J Gilbert; David E Parkin
Journal:  Gynecol Oncol       Date:  2008-09-06       Impact factor: 5.482

Review 8.  The value of advanced MRI techniques in the assessment of cervical cancer: a review.

Authors:  Evelyn Dappa; Tania Elger; Annette Hasenburg; Christoph Düber; Marco J Battista; Andreas M Hötker
Journal:  Insights Imaging       Date:  2017-08-21

9.  Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.

Authors:  Daniel Grossi Marconi; Jose Humberto Tavares Guerreiro Fregnani; Rodrigo Ribeiro Rossini; Ana Karina Borges Junqueira Netto; Fabiano Rubião Lucchesi; Audrey Tieko Tsunoda; Mitchell Kamrava
Journal:  BMC Cancer       Date:  2016-07-28       Impact factor: 4.430

10.  Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT).

Authors:  E J Alexander; J R Murray; V A Morgan; S L Giles; S F Riches; S Hazell; K Thomas; S A Sohaib; A Thompson; A Gao; D P Dearnaley; N M DeSouza
Journal:  Radiother Oncol       Date:  2019-09-05       Impact factor: 6.280

View more
  1 in total

Review 1.  Novel monodisperse FePt nanocomposites for T2-weighted magnetic resonance imaging: biomedical theranostics applications.

Authors:  Zhi-Xuan Chang; Chien-Hsiu Li; Yu-Chan Chang; Chi-Ying F Huang; Ming-Hsien Chan; Michael Hsiao
Journal:  Nanoscale Adv       Date:  2021-11-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.